Fevers, drenching night sweats, weight loss, significant or progressive lymphadenopathy, involvement of the bone marrow that is significant that leads to cytopenias, or if the disease is threatening the function of an important organ are among the reasons to start treatment, says Poh.
Continuing the Managed Healthcare Executive Between the Lines series, Philip Mease, MD, of Swedish Medical Center, Providence St. Joseph Health, and the University of Washington, asks Saakshi Khattri, MD, of the Icahn School of Medicine at Mount Sinai, to reflect on her real-world experience with bimekizumab's safety profile and the broader clinical takeaways from the BE BOLD trial.
People may not be fully aware of added cost exposures if they shift to bronze Affordable Care (ACA) plans, says Margaret A. Murray, M.P.A., CEO of the Association for Community Health Plans. Murray says the nonnetwork plans that the Trump administration is promoting will result in underinsurance.
Margaret A. Murray, M.P.A., CEO of the Association for Community Affiliated Plans, says outreach and texting will be key to keeping eligible Medicaid enrollees covered under new redetermination and work requirements.
Margaret A. Murray, M.P.A., CEO of the Association for Community Affiliated Plans, says ACAP opposes Medicaid work requirements but seeks common ground with CMS on issues such as program integrity.
Understand diagnosis, watchful waiting, and long-term risks in slow-growing lymphoma—monitoring symptoms, relapse, and transformation.
Learn how follicular lymphoma often appears later in life, shows subtle symptoms, and follows a relapsing course with remission cycles and transformation risk.
Oregon Health & Science University researchers found sensitive caregiving in infancy can offset ADHD risk linked to higher maternal inflammation in pregnancy, a new study shows.
A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact
In this installment of the Managed Healthcare Executive Between the Lines series, Philip Mease, MD, of Swedish Medical Center, Providence St. Joseph Health, and the University of Washington, walks through the actual 16-week efficacy and safety results from the BE BOLD head-to-head trial of bimekizumab versus risankizumab in active psoriatic arthritis.
Aligning payer criteria with the FDA label, rather than the trial's narrower enrollment rules, may determine how many patients with this costly, progressive disease actually gain access to treatment.
The FDA label reaches further than the pivotal trial's inclusion criteria, and DUPLEX's own subgroup data reveals where the treatment effect holds strongest and where it does not.
Tiffany Phung, Pharm.D., CSP, of UC Davis Health, discusses an alternative approach to clinical research and practice improvement ahead of HSES 2026.
Continuing the Managed Healthcare Executive Between the Lines series, moderator Philip Mease, MD, of Swedish Medical Center, Providence St. Joseph Health, and the University of Washington, and guest Saakshi Khattri, MD, of the Icahn School of Medicine at Mount Sinai, shift from the broader disease burden discussion to how biologics are actually being used in practice today, before laying out the design of the BE BOLD trial.
Will Carroll, Pharm.D., chief pharmacy officer at Sutter Health, discusses strategic priorities and his vision for specialty pharmacy growth.
Joseph Savasta, founder and CEO of pharmacy benefit manager HarmonyRx, discusses why the company keeps rejecting acquisition offers amid PBM consolidation.
Patel, senior vice president of trade relations and supply chain at MedImpact, discusses his career path and current responsibilities. at MedImpact.
Robyn S. Crosson, J.D., VP of government relations at Navitus Health Solutions, has won the PBMI Innovators Award for her work advancing transparency in pharmacy benefits.
A closely watched safety profile and a REMS program built for vigilance define how clinicians should approach monitoring patients starting on this dual receptor antagonist.
A missed primary endpoint obscured a proteinuria signal strong enough that regulators reconsidered what counts as meaningful evidence in FSGS, a recalibration with real implications for future trial design.
Ashley Holzworth-Nash, Pharm.D., head of product strategy and solutions at Evernorth, discusses her path from the pharmacy counter to shaping care models.
Raechele McMahan of Prescryptive Health says a cancer diagnosis at 17 and her son's type 1 diabetes made health care access personal before professional.
Patrick Gleason, Pharm.D., of Prime Therapeutics was named a 2026 PBMI Innovator for his work on cost-effective formulary strategy and real-world evidence generation.
Under CMS's new Medicaid work rule, a qualifying medical condition alone won't exempt enrollees. They must also show impairment in a daily living activity.
David Chen, Pharm.D., of Kaiser Permanente discusses how PBM reform could speed biosimilar adoption and lower drug costs.
Welcome back to another Managed Healthcare Executive Between the Lines series. In this opening episode, moderator Philip Mease, MD, Director of Rheumatology Research at Swedish Medical Center, Providence St. Joseph Health, and Clinical Professor at the University of Washington, is joined by Saakshi Khattri, MD, Director of the Center for Connective Tissue Diseases at the Icahn School of Medicine at Mount Sinai, to lay the groundwork for a discussion on the BE BOLD head-to-head trial of bimekizumab versus risankizumab in active psoriatic arthritis (PSA).
Eric Levine, M.P.H., principal at Avalere Health, explains why a diagnosis alone won't exempt someone from the Medicaid work requirements that go into effect in 2027.
CMS's new interim rule sets an 80-hour monthly work requirement for many Medicaid enrollees but leaves states some latitude on setting medical exemptions and verification processes.
Behind sparsentan's approval sits a trial built on stringent inclusion criteria and evolving endpoint science, raising hard questions about which real-world FSGS patients the data actually represents.
As sparsentan enters practice, corticosteroids and RAS inhibitors retain a role for select patients, while clinicians weigh how and when to transition existing therapy toward the newly approved option.
